title: [Impact of Bestim on the immunological status and clinical course of ulcer].
abstract: Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. This makes it necessary to include immunomodulators into the complex antiulcer treatment. The application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and scarring of the ulcer.
authors.forename: A G
authors.initials: AG
authors.lastname: Tkacheva
authors.forename: O F
authors.initials: OF
authors.lastname: Kalev
authors.forename: A I
authors.initials: AI
authors.lastname: Dolgushina
authors.forename: T V
authors.initials: TV
authors.lastname: Antipina
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004151:Dipeptides / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013276:Stomach Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D004151:Dipeptides; D007155:Immunologic Factors